Co-administration of an agent linked to an internalization...

Details Co-administration of an agent linked to an internalization... Co-administration of an agent linked to an internalization...

2008-11-26

2011-12-20

Kemmerer, Elizabeth C (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017700, C514S012200

Reexamination Certificate

active

08080518

ABSTRACT:
The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

REFERENCES:
patent: 7595297 (2009-09-01), Tymianski
patent: 2001/0008758 (2001-07-01), McHale et al.
patent: 2002/0032154 (2002-03-01), Peyman
patent: 2003/0083256 (2003-05-01), Rothbard et al.
patent: 2006/0276455 (2006-12-01), Lindsberg et al.
patent: 2007/0048310 (2007-03-01), Anderson
patent: 2007/0225209 (2007-09-01), Roch et al.
patent: WO 2010/144742 (2010-12-01), None
Takagi et al., 2000, J. Neurochemistry 74: 169-178.
Cui et al., 2007, Neurobiology of Disease 27:9901-9915.
Bassand et al., 1999, Eur. J. Neurosci. 11:2031-2043.
Bach et al. (2008, J. Med. Chem. 51:6450-6459).
Buonaguro et al. (1992, J. Virol. 66:7159-7167).
Spisani et al. (1990, Inflammation 14:55-60.
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for application PCT/US 08/85280 filed Dec. 2, 2008.
Blom, et al, “A method for determining whether hypotension cased by novel compounds in preclinical development results from histamine release” Journal of Pharma 49(20041 31-37.
PCT Search Report of Jan. 10, 2010 for application PCT/US2008/085280.
PCT Search Report and Written Opinion mailed Feb. 21, 2011 for application PCT/US2010/038226.
Aarts, M., et al., “Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions.” Science. 298(5594): 846-850 (Oct. 25, 2002).
Barr. M. L., et al., “Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury.” J. Thorac. Cardiovasc. Surg. 115(3): 631-636 (Mar. 1998).
Herce, H. D., et al. “Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes.” Proc. Natl. Acad. Sci. U.S.A. 104(52): 20805-20810 (Dec. 18, 2007).
Kurose, I., et al., “Ischemia/reperfusion-induced microvascular dysfunction: role of oxidants and lipid mediators.” Am.J. Physiol 272(6 pt 2): H2976-H2982 (Jun. 1997).
Mackins, C. J., et al., “Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J. Clin. Invest.” 116(4): 1063-1070 (Apr. 2006).
Sun, H. S., et al., “Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat.” Stroke. 39(9): 2544-2553 (Jul. 10, 2008).

Affiliated with

Also associated with

Rating

Co-administration of an agent linked to an internalization... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Co-administration of an agent linked to an internalization..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Co-administration of an agent linked to an internalization... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4260422